GlassScriptPhysician profile
James C Roberson
NPI 1003918558
$4,609.78
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $2,462 · 2023: $672 · 2024: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831 · Education: $23.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.75 |
| Education | $23.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,241.63 | 2021-2024 | Tremfya |
| Ucb, INC. | $457.82 | 2021-2024 | Cimzia |
| Abbvie INC. | $365.11 | 2022-2024 | Ubrelvy, Qulipta |
| Amgen INC. | $341.78 | 2022-2024 | Enbrel, Otezla, Tavneos |
| Glaxosmithkline, LLC. | $229.48 | 2022-2024 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $208.33 | 2022-2023 | Lupkynis |
| Lilly USA, LLC | $174.99 | 2022-2024 | Taltz |
| Pfizer INC. | $110.64 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $101.19 | 2023-2024 | |
| Ibsa Pharma INC. | $96.53 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.21 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $57.72 | 2024 | Saphnelo |
| Horizon Therapeutics Plc | $40.81 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $39.34 | 2023 | Acthar |
| Genzyme Corporation | $24.45 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $22.15 | 2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $19.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.